Quetiapine
- Generic Name
- Quetiapine
- Brand Names
- Seroquel
- Drug Type
- Small Molecule
- Chemical Formula
- C21H25N3O2S
- CAS Number
- 111974-69-7
- Unique Ingredient Identifier
- BGL0JSY5SI
- Background
Initially approved by the FDA in 1997, quetiapine is a second-generation atypical antipsychotic used in schizophrenia, major depression, and bipolar disorder. Quetiapine demonstrates a high level of therapeutic efficacy and low risk of adverse effects during long-term treatment. It is well-tolerated and a suitable option for some patients with high sensitivity to other drugs, such as Clozapine and Olanzapine.
- Indication
Quetiapine is used in the symptomatic treatment of schizophrenia. In addition, it may be used for the management of acute manic or mixed episodes in patients with bipolar I disorder, as a monotherapy or combined with other drugs. It may be used to manage depressive episodes in bipolar disorder. In addition to the above indications, quetiapine is used in combination with antidepressant drugs for the treatment of major depression.
Some off-label uses for this drug include the management of post-traumatic stress disorder (PTSD), generalized anxiety disorder, and psychosis associated with Parkinson's disease.
- Associated Conditions
- Bipolar 1 Disorder, Depressive Episodes, Generalized Anxiety Disorder, Major Depressive Disorder (MDD), Mixed manic depressive episode, Post Traumatic Stress Disorder (PTSD), Psychosis, Schizophrenia, Acute Manic episode
- Associated Therapies
- -
Effect of Quetiapine on Marijuana Withdrawal and Relapse
- Conditions
- Interventions
- First Posted Date
- 2008-08-28
- Last Posted Date
- 2017-08-18
- Lead Sponsor
- New York State Psychiatric Institute
- Target Recruit Count
- 20
- Registration Number
- NCT00743366
- Locations
- 🇺🇸
New York State Psychiatric Institute, New York, New York, United States
Efficacy of Bifeprunox in Patients With Schizophrenia
- First Posted Date
- 2008-06-25
- Last Posted Date
- 2010-09-27
- Lead Sponsor
- H. Lundbeck A/S
- Target Recruit Count
- 346
- Registration Number
- NCT00704509
- Locations
- 🇮🇳
IN006, Chennai, India
🇮🇳IN008, Ahmedabad, India
🇮🇳IN011, Ahmedabad, India
Quetiapine in Co-Morbid Depressive and Anxiety Disorders
- Conditions
- Interventions
- First Posted Date
- 2008-06-03
- Last Posted Date
- 2014-08-21
- Lead Sponsor
- Centre for Addiction and Mental Health
- Target Recruit Count
- 108
- Registration Number
- NCT00688818
- Locations
- 🇨🇦
Centre for Neuropsychiatric Study, Markham, Ontario, Canada
🇨🇦Credit Valley Medical Arts Centre, Mississauga, Ontario, Canada
🇨🇦Centre for Addiction and Mental Health, Toronto, Ontario, Canada
Quetiapine in Postpartum Depression
- First Posted Date
- 2008-05-21
- Last Posted Date
- 2010-12-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 5
- Registration Number
- NCT00681668
- Locations
- 🇩🇪
Research Site, Herten, Westfalen-Lippe, Germany
Seroquel for Frequent, Heavy Drinkers
- First Posted Date
- 2008-05-08
- Last Posted Date
- 2014-09-17
- Lead Sponsor
- University of Pennsylvania
- Target Recruit Count
- 156
- Registration Number
- NCT00674765
- Locations
- 🇺🇸
University of Pennsylvania, Treatment Research Center, Philadelphia, Pennsylvania, United States
Anxiety in Recovering Opiate Dependence
- Conditions
- Interventions
- First Posted Date
- 2008-04-29
- Last Posted Date
- 2013-02-18
- Lead Sponsor
- Beth Israel Medical Center
- Target Recruit Count
- 14
- Registration Number
- NCT00668265
- Locations
- 🇺🇸
Su Casa Methadone-to-Abstinence Rehabilitation, New York, New York, United States
Study in Schizophrenic In-patients Treated With Quetiapine Prolong or Oral Risperidone at Flexible Dose
- First Posted Date
- 2008-04-17
- Last Posted Date
- 2010-09-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 29
- Registration Number
- NCT00660595
- Locations
- 🇫🇮
Research Site, Turku, Finland
Efficacy of Bifeprunox in Patients With Schizophrenia
- First Posted Date
- 2008-04-15
- Last Posted Date
- 2010-09-27
- Lead Sponsor
- H. Lundbeck A/S
- Target Recruit Count
- 227
- Registration Number
- NCT00658645
- Locations
- 🇷🇺
RU017, Chita, Russian Federation
🇷🇺RU005, Moscow, Russian Federation
🇷🇴RO002, Bucuresti, Romania
Efficacy Study Exploring the Effects on Cognition of Sertindole Versus Comparator in Patients With Schizophrenia
- First Posted Date
- 2008-04-09
- Last Posted Date
- 2014-05-28
- Lead Sponsor
- H. Lundbeck A/S
- Target Recruit Count
- 264
- Registration Number
- NCT00654706
- Locations
- 🇺🇸
US012, Baltimore, Maryland, United States
🇺🇸US020, Dallas, Texas, United States
🇺🇸US014, Stanford, California, United States
Effect of Quetiapine on Sleep Architecture in Bipolar Depression and Major Depressive Disorder
- First Posted Date
- 2008-02-15
- Last Posted Date
- 2015-12-16
- Lead Sponsor
- Queen's University
- Target Recruit Count
- 15
- Registration Number
- NCT00616889
- Locations
- 🇨🇦
Pccc, Mhs, Kingston, Ontario, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.